Shares of Agios Pharmaceuticals (NASDAQ:AGIO) reached a new 52-week high and low on Friday . The stock traded as low as $89.33 and last traded at $87.91, with a volume of 208507 shares changing hands. The stock had previously closed at $87.48.
Several analysts have weighed in on AGIO shares. BidaskClub lowered Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, December 16th. Oppenheimer set a $83.00 target price on Agios Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, December 26th. ValuEngine raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Zacks Investment Research raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $68.00 target price on the stock in a report on Tuesday, January 9th. Finally, Royal Bank of Canada upped their target price on Agios Pharmaceuticals to $91.00 and gave the company an “outperform” rating in a report on Thursday, January 18th. They noted that the move was a valuation call. Three analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $87.00.
The company has a market cap of $4,834.36, a P/E ratio of -13.16 and a beta of 1.98.
In related news, major shareholder Corp /De/ Celgene acquired 851,154 shares of the firm’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were acquired at an average price of $67.00 per share, with a total value of $57,027,318.00. Following the completion of the purchase, the insider now directly owns 1,374,599 shares in the company, valued at $92,098,133. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, insider Scott Biller sold 3,000 shares of the stock in a transaction on Thursday, April 5th. The shares were sold at an average price of $75.20, for a total value of $225,600.00. Following the sale, the insider now directly owns 60,196 shares in the company, valued at approximately $4,526,739.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 210,880 shares of company stock worth $16,368,948. Corporate insiders own 5.43% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of AGIO. Nationwide Fund Advisors lifted its position in Agios Pharmaceuticals by 37.8% during the third quarter. Nationwide Fund Advisors now owns 6,344 shares of the biopharmaceutical company’s stock worth $423,000 after buying an additional 1,740 shares during the period. Bank of New York Mellon Corp lifted its position in Agios Pharmaceuticals by 3.9% during the third quarter. Bank of New York Mellon Corp now owns 176,405 shares of the biopharmaceutical company’s stock worth $11,775,000 after buying an additional 6,632 shares during the period. Ameriprise Financial Inc. lifted its position in Agios Pharmaceuticals by 15.0% during the third quarter. Ameriprise Financial Inc. now owns 57,504 shares of the biopharmaceutical company’s stock worth $3,838,000 after buying an additional 7,510 shares during the period. Macquarie Group Ltd. purchased a new position in Agios Pharmaceuticals during the third quarter worth about $245,000. Finally, Legal & General Group Plc lifted its position in Agios Pharmaceuticals by 29.8% during the third quarter. Legal & General Group Plc now owns 16,241 shares of the biopharmaceutical company’s stock worth $1,084,000 after buying an additional 3,724 shares during the period. 82.41% of the stock is currently owned by institutional investors and hedge funds.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.